The collaboration aims to create an innovation pipeline for specialized pediatric tests across oncology, metabolic disease, and autoimmune conditions.
Labcorp and Children’s Hospital of Philadelphia (CHOP) announced a collaboration to accelerate the discovery, development, and nationwide availability of specialized pediatric diagnostics. The partnership combines CHOP’s pediatric research and clinical expertise with Labcorp’s national diagnostic infrastructure and commercialization capabilities.
The collaboration focuses on expanding access to advanced diagnostic testing for children and families. “By pairing CHOP’s pediatric leadership with Labcorp’s nationwide reach, we seek to deliver important new and specialized tests to children and their families more efficiently and at greater scale,” says Stephen R Master, MD, PhD, division chief and director of metabolic and advanced diagnostics at Children’s Hospital of Philadelphia, in a release.
Pediatric Innovation Pipeline
A central component of the agreement is the creation of a joint pediatric diagnostics innovation pipeline. Labcorp and CHOP will work together to identify and develop new tests and technologies to streamline the path from clinical discovery to national availability.
Pediatric-specific diagnostics are designed to provide age-appropriate insights by accounting for unique biology, developmental stages, and physiological ranges. These factors are often overlooked by traditional adult-oriented tests. The collaboration intends to make these diagnostics available across several clinical areas, including oncology, metabolic disease, and autoimmune conditions.
Improving Clinical Access
The organizations aim to provide clinicians and health systems with pediatric testing for cancer, genetics, immune disorders, and rare diseases. This access is intended to enable earlier and more precise diagnoses for pediatric patients.
“Labcorp and CHOP share a commitment to advancing pediatric care. By combining CHOP’s deep pediatric expertise with Labcorp’s scientific capabilities and national reach, we can bring pediatric diagnostic innovations to patients faster and make advanced testing accessible to many more families,” says Bryan Vaughn, executive vice president, diagnostics at Labcorp, in a release.
The partnership marks an effort to bridge the gap between pediatric scientific research and clinical diagnostic availability. “Today’s announcement marks an important milestone at the intersection of scientific research and collaboration,” says Joseph Mitchell, MD, president at Children’s Hospital of Philadelphia, in a release. “Our commitment to innovation has always been driven by one goal: improving the lives of children. By working closely with Labcorp, we can create the breakthroughs that children and families need—today and in the years to come.”
